These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25347912)

  • 21. Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation.
    Muruganandam M; Sandhu H
    J Clin Rheumatol; 2016 Oct; 22(7):384. PubMed ID: 27488454
    [No Abstract]   [Full Text] [Related]  

  • 22. Bisphosphonate-associated orbital inflammation--a case report and review.
    Peterson JD; Bedrossian EH
    Orbit; 2012 Apr; 31(2):119-23. PubMed ID: 22489855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
    Santini D; Vincenzi B; Caraglia M; Tonini G
    Ann Oncol; 2007 Jan; 18(1):201-202. PubMed ID: 17021272
    [No Abstract]   [Full Text] [Related]  

  • 24. Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature.
    Jin X; Shou Z; Shao Y; Bian P
    Arch Osteoporos; 2021 Jun; 16(1):104. PubMed ID: 34180015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
    Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid induced osteonecrosis of tibia and femur.
    Gupta S; Jain P; Kumar P; Parikh PM
    Indian J Cancer; 2009; 46(3):249-50. PubMed ID: 19574685
    [No Abstract]   [Full Text] [Related]  

  • 28. Undetectable Urine Calcium in a Gastric Bypass Patient.
    Campbell ST; Santen RJ; Bruns DE
    Clin Chem; 2016 Aug; 62(8):1161. PubMed ID: 27471247
    [No Abstract]   [Full Text] [Related]  

  • 29. Acute blepharitis: an unusual complication of zoledronic acid.
    Osta LE; Osta BE
    Int J Rheum Dis; 2017 Apr; 20(4):515-518. PubMed ID: 26412501
    [No Abstract]   [Full Text] [Related]  

  • 30. Histopathological features of osteonecrosis of the jaw associated with bisphosphonates.
    Paparella ML; Brandizzi D; Santini-Araujo E; Cabrini RL
    Histopathology; 2012 Feb; 60(3):514-6. PubMed ID: 22168273
    [No Abstract]   [Full Text] [Related]  

  • 31. Possible zoledronic acid-induced dermatomyositis.
    Apalla Z; Tzellos T; Lallas A; Sotiriou E; Lefaki I
    Clin Exp Dermatol; 2012 Apr; 37(3):309-11. PubMed ID: 22007911
    [No Abstract]   [Full Text] [Related]  

  • 32. The incidence of acute anterior uveitis after intravenous zoledronate.
    Patel DV; Horne A; House M; Reid IR; McGhee CN
    Ophthalmology; 2013 Apr; 120(4):773-6. PubMed ID: 23290982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review.
    Böni C; Kordic H; Chaloupka K
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):367-9. PubMed ID: 23629782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A once-yearly IV bisphosphonate for osteoporosis.
    Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
    [No Abstract]   [Full Text] [Related]  

  • 35. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 36. [Not Available].
    Tamborrini G; Moser F; Sterki Novakova K
    Praxis (Bern 1994); 2018 Jan; 107(2):106-107. PubMed ID: 29338633
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

  • 38. Zoledronic acid infusion and orbital inflammatory disease.
    Sharma NS; Ooi JL; Masselos K; Hooper MJ; Francis IC
    N Engl J Med; 2008 Sep; 359(13):1410-1. PubMed ID: 18815406
    [No Abstract]   [Full Text] [Related]  

  • 39. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
    Wynn RL
    Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815
    [No Abstract]   [Full Text] [Related]  

  • 40. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.